
Telix Pharmaceuticals (ASX: TLX) is recovering after a sharp biotech sell-off driven by regulatory and legal concerns. Renewed investor confidence follows strong revenue growth, progress in Phase 3, and a Regeneron partnership, with FY2026 revenue nearing US$1 billion and pipeline milestones advancing.

EBR Systems has fallen sharply after a major capital raise sparked dilution concerns. Despite the sell-off, the company continues to expand the commercialisation of its FDA-approved WiSE CRT heart-failure technology, supported by growing implant volumes, clinical studies, and international regulatory progress.

Genesis Minerals (ASX: GMD) is accelerating production, generating exceptional cash flow, and advancing its Tower Hill growth engine while the stock approaches key breakout levels. We assess fundamentals, catalysts, risks, and technical signals.

WiseTech Global shares have fallen sharply amid bearish sentiment and heavy selling pressure. The logistics software company continues to expand its CargoWise platform and invest in AI and digital trade solutions, but investors remain cautious as the stock trades near multi-month lows.

Judo Capital (ASX: JDO) has dropped sharply after a credit-quality shock, lifting cost-of-risk guidance and cutting profit forecasts. Heavy selling, oversold technicals, and weak sentiment now define the stock, though long-term growth signals remain partly intact.
.webp&w=828&q=75)
Iluka Resources (ASX: ILU) advances its Eneabba rare earth refinery and Balranald ramp‑up, positioning as Australia’s critical minerals leader with strong government backing and margin resilience through 2026
...